FindTrial
Sign In

To check MELD 3.0 and MELD-Na for predicting mortality in patients with liver cirrhosis

Model for end-stage liver disease-3.0 and model for end-stage liver disease-sodium in predicting mortality in cirrhosis- A comparative study - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/01/079246
Enrollment
142
Registered
2025-01-22
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K746- Other and unspecified cirrhosis ofliver

Interventions

Intervention1: NA: NA Control Intervention1: NA: NA

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age of 18 and above, irrespective of gender. Patients diagnosed with liver cirrhosis and clinically significant portal hypertension based on clinical, radiological, and biochemical parameters.

Exclusion criteria

Exclusion criteria: ACLF Ischemic hepatitis Hepatocellular carcinoma Any extrahepatic malignancy with a life expectancy of less than 3 months Any severe extrahepatic disease that has an impact on survival of less than 3 months

Design outcomes

Primary

MeasureTime frame
To compare MELD-Na and MELD 3.0 in predicting the 30 days and 90 days mortality, liver transplantation and death in patients with cirrhosisTimepoint: 0, 28 and 90 days—

Secondary

MeasureTime frame
Gender specific mortality and etiology specific mortality prediction using MELD-Na and MELD-3.0 scores.Timepoint: 0, 28 and 90 days—

Countries

India

Contacts

Public ContactDr R Sriman Narayan Reddy

Kasturba Medical College

bhat.ganesh@manipal.edu9900791615

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026